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Background: Signal Regulatory Protein γ (SIRPγ) is a member of a closely related family of three cell surface
receptors implicated in modulating immune/inflammatory responses. SIRPγ is expressed on T lymphocytes where it
appears to be involved in the integrin-independent adhesion of lymphocytes to antigen-presenting cells. Here we
describe the first full length structure of the extracellular region of human SIRPγ.
Results: We obtained crystals of SIRPγ by making a complex of the protein with the Fab fragment of the anti-SIRP
antibody, OX117, which also binds to SIRPα and SIRPβ. We show that the epitope for FabOX117 is formed at the
interface of the first and second domains of SIRPγ and comprises residues which are conserved between all three
SIRPs. The FabOX117 binding site is distinct from the region in domain 1 which interacts with CD47, the
physiological ligand for both SIRPγ and SIRPα but not SIRPβ. Comparison of the three domain structures of SIRPγ
and SIRPα showed that these receptors can adopt different overall conformations due to the flexibility of the linker
between the first two domains. SIRPγ in complex with FabOX117 forms a dimer in the crystal. Binding to the Fab
fixes the position of domain 1 relative to domains 2/3 exposing a surface which favours formation of a homotypic
dimer. However, the interaction appears to be relatively weak since only monomers of SIRPγ were observed in
sedimentation velocity analytical ultracentrifugation of the protein alone. Studies of complex formation by
equilibrium ultracentrifugation showed that only a 1:1 complex of SIRPγ: FabOX117 was formed with a dissociation
constant in the low micromolar range (Kd = 1.2 +/− 0.3 μM).
Conclusion: The three-domain extracellular regions of SIRPs are structurally conserved but show conformational
flexibility in the disposition of the amino terminal ligand-binding Ig domain relative to the two membrane proximal
Ig domains. Binding of a cross-reactive anti-SIRP Fab fragment to SIRPγ stabilises a conformation that favours SIRP
dimer formation in the crystal structure, though this interaction does not appear sufficiently stable to be observed
in solution.
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Members of the signal regulatory protein family (SIRP) play
important roles in the regulation of the immune response
in man [1]. The family comprises three type I transmem-
brane glycoproteins (α, β, γ) each with an extracellular re-
gion consisting of three Ig-like domains followed by a
single transmembrane sequence and a cytoplasmic domain
which varies in length between the three SIRPs. SIRPs are
classified as “paired receptors” since they show the follow-
ing characteristics: (1) they are encoded by different genes
arranged in a gene cluster, (2) they share significant se-
quence homology in their extracellular domains and (3)
they comprise both activating and inhibitory members.
Thus SIRPα delivers an inhibitory signal via immuno-
receptor tyrosine-based inhibition motifs (ITIMs) located
in the cytoplasmic domain of the protein as well as
interacting with the ligand CD47 [2]. SIRPβ delivers an acti-
vating signal through association with DAP12, a transmem-
brane adaptor protein with an immunoreceptor tyrosine-
based activation motif (ITAM), but does not bind to CD47
[1]. By contrast, SIRPγ appears to have no signaling func-
tion but does bind to CD47, though this interaction is ten
times weaker than that of SIRPα [3]. Unlike the other SIRP
proteins, SIRPγ is expressed by T cells where it interacts
with CD47 on the surface of the cell, resulting in increased
cell-cell adhesion in an integrin-independent manner [4].
Therefore, it is thought that SIRPγ may be involved in T
cell responses as an accessory protein [4]. Note, SIRPγ was
originally called SIRPβ2 but this term is no longer used [5].
There has been considerable interest in the structure
of the SIRP family with regard to the subtle differences
in ligand binding specificity [6,7] and a putative relation-
ship to primitive antigen receptors [8]. Crystal structures
have been determined for the N terminal domains of
SIRPα [9,10], SIRPβ and SIRPγ [11], a full extracellular
region of SIRPα [12] and a complex of the N-terminal
domain of SIRPα and CD47 [11].
In this paper we present the X-ray crystal structure of
the complete extracellular portion of SIRPγ co-crystallized
with the Fab fragment of the OX117 monoclonal antibody,
which recognises SIRPα, SIRPβ and SIRPγ [3]. The Fab
fragments of antibodies have been used extensively as co-
crystallization chaperones [13,14] and binding to Fab frag-
ments of OX117 facilitated the crystallization of SIRPγ in
this study. The eptiope recognised by OX117 involved res-
idues in both domains 1 and 2 (d1 and d2) of SIRPγ and
was distinct from the CD47 binding site on d1. Interest-
ingly, SIRPγ formed a dimer in the crystal structure
through an interface between d1 and d2.
Results and discussion
Overall structure
In contrast to SIRPα [12], attempts to grow diffraction
quality crystals of the full three domain extracellularregion of SIRPγ proved unsuccessful. Therefore an anti-
body chaperone approach was adopted using the Fab
fragment of a SIRP monoclonal antibody (OX117) that
had previously been generated [3,15]. Both Fab frag-
ments of OX117 and the extracellular region of SIRPγ
were produced as recombinant proteins in mammalian
cells. Diffracting crystals of the FabOX117: SIRPγ complex
were successfully obtained following de-glycosylation of
the SIRPγ: FabOX117 protein complex using endoglyco-
sidase F1. The structure of the complex was solved to
2.5 Å resolution by molecular replacement. The crystallo-
graphic asymmetric unit contains a SIRPγ dimer, with
each SIRPγ monomer bound to a FabOX117 (Figure 1A).
The final refined model has a R-factor of 0.200 (R-free:
0.259) with root mean square deviations (rmsds) of
0.007 Å for bond lengths and 1.2° for bond angles from
the ideal values. The C-terminal end of d3 of SIRPγ is flex-
ible, residues 294–295 and 317–332 in one molecule, and
residues 232–239, 289–298 and 316–332 in another are
not defined in the electron density map and not included
in the model. The two SIRPγ molecules can be supe-
rimposed with a rmsd of 0.61 Å for 294 equivalent Cα
atoms, while the rmsd is 0.63 Å for 428 equivalent Cα
atoms between the two FabOX117 molecules. Of the 4 po-
tential glycosylation sites in each SIRPγ molecule, one at
residue 240 has sufficient density allowing the N-linked
N-acetylglucosamine to be modelled; weak electron dens-
ity attached to residue 215 suggests the presence of glyco-
sylation. There is no evidence in the electron density map
for the modification at Asn281 and Asn289, which con-
trasts with the observations reported for the structure of
SIRPα [12]. The C-terminal His6 tag from one of the Fab
heavy chains is ordered, presumably due to crystal con-
tacts. Two His residues, at position 1 and 5, together with
a water molecule and His56 from a symmetry related
SIRPγ bind a zinc ion with the canonical tetrahedral
coordination.
The Fab binding site
From the structure it can be seen that the antibody Fab
fragment binds to both d1 and d2 of SIRPγ (Figure 1A).
The light chain variable region (Vl) appears to be
inserted between the two domains contacting residues in
both d1 and d2, whereas the heavy chain variable do-
main (Vh) only interacts with d1. Comparison of bound
and unbound FabOX117 (PDB id 3DIF) shows only
small changes in conformation upon binding (Figure 1B).
Alignment using PDBeFold [16] of the Fd region (Vh
and CH1 domains) gives a rmsd of 0.6 Å for the Cα
backbone for 208 out of 220 residues. Regions of the Fd
fragment that were disordered in the unbound Fab
structure, namely the Vh loop consisting of residues
G133 to S140 and the C-terminal residues 219 to 220
become ordered on binding to the antigen. For the light
Figure 1 Structure of the FabOX117: SIRPγ complex. (A)
Overview of the FabOX117: SIRPγ complex showing two SIRPγ
(coloured magenta and pink) molecules forming a dimer in the
asymmetric unit each bound to a Fab fragment of the monoclonal
antibody, OX117 [3], (heavy chain coloured cyan, light chain
coloured green) (B) Overlay of bound/unbound (PDB id 3DIF15)
FabOX117 showing the change in position of CDR3 of the heavy
chain variable domain in bound (cyan) compared to the unbound
(grey) FabOX117. The key residues involved in the interaction
between Vh and d1 of SIRPγ (coloured orange) are shown in stick
representation. (C) Comparison of SIRPγ: FabOX117 (coloured as
Figure 1A) and SIRPα: CD47 complexes (coloured grey and blue
respectively) showing that both CD47 and FabOX117 can bind to
SIRPγ d1 at the same time.
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of 214 residues. The most significant conformational
change in FabOX117 upon binding to SIRPγ is the re-
positioning of the side-chain of R103 in the third Comple-
mentarity Determining Region (CDR3) of Vh (Figure 1B).
R103 forms a network of hydrogen bonds with SIRPγ d1
involving Q8 and E10 in the loop connecting β-strands A1
and A2 and G109 in the G1/G2 loop (Figure 1B). Add-
itional hydrogen bond interactions between FabOX117
and SIRPγ are observed between Y92 in Vl CDR3 and
K11 and L12 in the A1/A2 loop of SIRPγ and between
S26 of Vl CDR1 and D149 in d2 of SIRPγ. All these resi-
dues are conserved between SIRPα, β and γ indicating that
OX117 would bind in a similar way to all three SIRPs,
consistent with the cross-reactivity data previously pub-
lished for this antibody [3].
The structure of the isolated d1 domain of SIRPγ has
been solved previously (PDB id 2JJW [11]). Overlaying
this structure onto the full length SIRPγ, showed that
binding of the Fab fragment to d1 did not change the
conformation of the domain. Thus alignment of the two
d1 structures gave a rmsd for the Cα backbone of 0.5 Å
for 109/116 amino acids, with the loop comprising G97
to E100 becoming ordered in the complex. Overall,
binding of the FabOX117 to SIRPγ appears to result in
very little conformational change in either the antibody
or antigen.
The crystal structure of d1 of SIRPα in complex with
CD47 has been solved by Hatherley et al. [11]. When
the d1 of the FabOX117: SIRPγ crystal structure is
aligned with the SIRPα(d1): CD47 structure (PDB id
2JJS), the locations where Fab and CD47 bind to SIRPγ
do not overlap (Figure 1C). The main contact residues
for CD47 are in three loops connecting strands B2-C, D-E
and F-G1. This suggests that SIRPγ could bind both
FabOX117 and CD47 at the same time.
Comparison of SIRPγ with SIRPα
Comparison of the full length extracellular three domain
structure of SIRPγ with that of SIRPα (PDB id 2WNG
[12]) shows a high level of structural similarity for the
individual domains (d1-d3) (Figure 2A). One small dif-
ference is the relative length of the C’ and D strands in
the d3 domains which are short and long respectively in
SIRPγ and the opposite in SIRPα, though this does not
alter the overall topology of the d3 domains (Figure 2B).
However, there is a significant difference in the relative
orientation of the three domains between the two SIRP
structures (Figure 2A). Thus, in the superimposition of
d1 of SIRPγ onto the d1 of SIRPα (rmsd of 0.60 Å for
105 Cα atoms out of 114 residues), the d2-d3 domains
of the two proteins are rotated by 66° with respect to
each other (Figure 2A). The difference in the relative ar-
rangement of d1 and d2-d3 in the two SIRPs would
Figure 2 Comparison of the structure of SIRPα and SIRPγ. (A)
Overlay of SIRPα (PDB id 2WNG [12]) (coloured grey) SIRPγ (coloured
magenta) and (B) Cartoon of the secondary structure of the d3
domains of SIRPα and SIRPγ.
Figure 3 SIRPγ dimer interface. (A) SIRPγ dimer showing the
head-to-head interaction between the adjacent SIRPγ molecules
(coloured pink and magenta) (B) Close-up of the SIRPγ dimer
interface between domains 1 (d1) and 2 (d2) with residues that
contribute to hydrogen-bonding shown in stick representation
(d1 coloured grey and d2 coloured orange).
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interactions between FabOX117 VL and d2 observed in
SIRPγ would not be possible in the SIRPα structure shown
in Figure 2 (PDB id 2WNG). This suggests that there is
some flexibility in the d1-d2 inter-domain region as OX117
has previously been shown to bind to all three SIRPs [3].
Interestingly, in contrast to the structure of SIRPα alone
[12], the two SIRPγ molecules bound to FabOX117
formed a head-to head dimer in the crystal structure
(Figure 1A) with a contact area of about 1130 Å2 and a
Complex Formation Significance Score [17] of 0.78. This
is at the lower end of the range considered to be phy-
siological significant (1600 +/− 400 Å2) [18] though it is
comparable to the contact surface area (1150 Å2) and sig-
nificance score (0.74) for the SIRPγ: Fab interface. It there-
fore appears to be non-trivial. The two SIRPγ molecules
form an arch-like structure spanning a distance of ap-
proximately 160 Å with the Fab fragments binding to the
outer surface of the arch (Figure 3A). Dimer formation ap-
pears to be a consequence of the relative orientation of d1
with respect to d2 which is imposed by the Fab binding.
The interface between the two SIRPγ chains comprises a
number of hydrogen-bond interactions between residues
in d1 and d2, e.g. T88-D169, L114-S174, E111-G172 and a
salt bridge R180-E47 (Figure 3B). Six of these interface
residues are conserved between all three SIRP sequences,
with the other two showing relatively conservative substi-
tutions (R180H and L114V).
Analysis of the SIRPγ: FabOX117 complex by analytical
ultracentrifugation
The observation that SIRPγ is dimeric in the crystal, poses
the question as to whether this self-association occurs insolution. Sedimentation velocity analytical ultracentrifuga-
tion experiments were carried out on both SIRPγ and
FabOX117 proteins individually. Experimentally deter-
mined sedimentation coefficients, frictional ratios and mo-
lecular weights were compared to values calculated from
the coordinates of their crystal structures using US-
SOMO [19] (Table 1). The results showed that SIRPγ was
monodisperse and behaved as a monomer. A single spe-
cies was also observed for FabOX117 which corresponded
to the assembled light and heavy chain. Sedimentation
velocity experiments of a 2:1 stoichiometric mixture of
SIRPγ: FabOX117 gave two peaks at 2.70 S and 4.85 S
(Figure 4A). The first peak was consistent with the calcu-
lated and measured value for SIRPγ alone, whilst the sec-
ond peak corresponded to the sedimentation coefficient
calculated for a 1:1 complex of SIRPγ and FabOX117
(Table 1; marked ‘A’ in Figure 4A). A 1:2 mixture of SIRPγ
and FabOX117 gave a single skewed distribution around a
sedimentation coefficient of 4.5 S (Figure 4A), close to that
determined for the 1:1 complex. We interpret this result
as follows: under the conditions where there is a two-fold
molar excess of the FabOX117 over the SIRPγ protein, a
1:1 complex with SIRPγ is formed, which partially dissoci-
ates during sedimentation. Since the free FabOX117 has a
Table 1 Hydrodynamic parameters
Sample M0app
a S020;w
b f
f 0
 
app
b Mcalc
c Scalc
c f
f 0
 
calc
c
Fab 51.2 3.7 1.4 48.4 3.81 1.22
Sirp 39.4 2.7 1.6 42.6 2.52 1.46
1:1 Complex 91.0d 4.8 1.5 91.0 4.85 1.42
2:2 Complex Nd Nd Nd 182.0 7.25 1.48
acalculated using SEDANAL. Units are in kilodaltons.
bdetermined from sedimentation velocity. Units are in S.
ccalculated from the PDB file using US-SOMO. Units are the same for the
observed parameters.
Nd not determined.
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complex (4.85 S compared to 4.5 S) there is no resolution
of the bound and unbound FabOX117 into individual
peaks, and a skewed composite peak observed. However
the sedimentation coefficient of SIRPγ alone is sufficiently
different from the complex (2.5 S vs. 4.5 S) that a peak cor-
responding to the SIRPγ alone can be resolved (Figure 4A).
The theoretical basis for this behaviour has been described
previously by Cann, Winzor and co-workers [20,21]).
Nonetheless, if the SIRPγ: FabOX117 formed a 2:2 com-
plex, as observed in the crystal structure, then a species
sedimenting at 7.25 S would be expected (see Table 1;
marked ‘B’ in Figure 4A). However no such higher order
species were observed in any of the sedimentation velocity
experiments.
To assess the strength of the SIRPγ: FabOX117 inter-
action, sedimentation equilibrium centrifugation experi-
ments were carried out on 2:1, 1:1 and 1:2 stoichiometric
mixtures of SIRPγ: FabOX117. Data were extracted using
SEDFIT v14.1 [22] and processed with SEDPHAT [23].
The results did not fit a single species model indicating
that multiple forms were present in solution (Figure 4B).
However, the data fitted well to an A + B ↔ AB model.
From this model the derived dissociation constant was de-
termined to be 1.2 (± 0.3) μM, indicating only a moder-
ately strong antibody: antigen interaction. Such a value
would also explain the behaviour of the sedimentation vel-
ocity profiles seen in Figure 4A, since at the loading con-
centration used, there would be a small amount of
dissociation into individual components giving rise to
skewed peaks in the c(s) plot (Figure 4A).
We conclude that the 2:2 SIRP: FabOX117 complex ob-
served in the crystal structure is not formed in solution
under the conditions of the AUC experiments. It is im-
portant to note that the highest protein concentration of
the SIRPγ: FabOX117 mixture used in the AUC experi-
ments was 1 mg/ml (corresponding to 13.7 μM) compared
to 16.8 mg/ml (230 μM) for crystallization. Therefore it is
possible that the 2:2 complex predominates at high con-
centrations of the SIRPγ FabOX117 mixture. However we
calculate that this would require that the dissociation con-
stant of the 2:2 complex is </= 10 μM. If this was the case
Figure 4 Analytical ultracentrifugation of SIRPγ, FabOX117 and
SIRPγ: FabOX117 complexes. (A) Sedimentation velocity
distributions for SIRPγ, FabOX117, a 2:1 and a 1:2 mixture of SIRPγ:
FabOX117. Initial sedimentation distributions were analysed in
SEDFIT, whereas data were subsequently fitted in SEDANAL [22].
(B) Sedimentation equilibrium data of SIRPγ: FabOX117 were
obtained at 2:1, 1:1 and 1:2 stoichiometric ratios; for clarity, only
the data at 2:1 ratio is shown. Sedimentation equilibrium was
attained at 15 000 rpm (black), 20 000 rpm (red), 28 000 rpm
(green) and 36 000 rpm (yellow with black dots). Data were
extracted with SEDFIT [22] and analysed in SEDPHAT [23]. A single
species model did not fit the data. The data were then fitted to an
A + B ↔ C model where A is SIRPγ, B is FabOX117 and C is the 1:1
complex; this fit is represented by the solid black line going
through each of the data traces.
Table 2 X-ray data collection and refinement statistics
Data collection
X-ray source Diamond I03
Wavelength (Å) 0.97630
Space group P21212
Unit cell (Å) a = 140.4, b = 174.2, c = 81.7
Resolution range (Å) 30.0 – 2.50 (2.59-2.50)
Unique reflections 71197 (7000)
Completeness (%) 100 (100)
Redundancy 12.3 (10.5)
Average I/σI 14.9 (2.1)
Rmerge 0.157 (−−)
Refinement
Resolution range (Å) 30.0 – 2.50
No. of atoms (protein/other atoms) 11212/323
Rms bond length deviation (Å) 0.008
Rms bond angle deviation (°) 1.2
Mean B-factor (protein/other atoms[Å2]) 38/54
Residues in preferred regions (%) 1112 (89.5)
Residues in allowed regions (%) 128 (10.3)
Residues in disallowed regions (%) 3 (0.2)
aRwork and Rfree are defined by R = Σhkl||Fobs| − |Fcalc||/Σhkl|Fobs|, where h,k,l are
the indices of the reflections (used in refinement for Rwork; 5%, not used in
refinement, for Rfree), Fobs and Fcalc are the structure factors, deduced from
measured intensities and calculated from the model, respectively.
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the concentration of 13.7 μM used in the sedimentation
velocity experiments. The results of the AUC analyses
imply that self-association of SIRP γ only occurs, if at all,
at very high protein concentrations and therefore is un-
likely to be physiologically relevant.
Conclusions
A cross-reactive anti-SIRP monoclonal antibody (OX117)
has proved useful in crystallizing human SIRPγ and subse-
quently obtaining the structure of the antibody: antigen
complex. This has enabled the cross-reactive epitope to be
mapped to the first and second domains of SIRPγ distal
from the CD47 ligand binding site on domain 1. The
structure of the FabOX117: SIRPγ complex has also re-
vealed the potential for SIRPs to form head-to-head di-
mers through an interaction between the domains 1 and 2
on adjacent molecules in the crystal. However this inter-
action was not observed in solution, so its physiological
significance is questionable. Comparison of the three do-
main structures of SIRPγ and SIRPα showed that these re-
ceptors can adopt different overall conformations due to
the flexibility of the linker between the first two domains.
Given the sequence similarity between all members of the
SIRP family it seems likely that this is a property shared by
all of the receptors.
Methods
Protein production
SIRPγ and the Fab fragment of the anti-SIRP monoclonal
antibody, OX117 [3] (FabOX117), were expressed as re-
combinant proteins in mammalian cells. FabOX117 was
produced by co-transfection of HEK 293 T cells (available
from the American Type Culture Collection as CRL-
11268) with vectors encoding the heavy and light chain
genes using a CompacT SelecT robotic system (The Auto-
mation Partnership, Royston, UK) [24]. The Fab fragment
was purified from the cell culture media by nickel affinity
chromatography followed by size exclusion chromato-graphy [15]. The extracellular region of SIRPγ was
expressed using the SIRPα leader sequence residues 1–30
(accession number CAA71403) followed by residues
29–347 of SIRPγ (accession number NP_061026) with a
C-terminal tag of STRHHHHHH using the pEE14 vector
in CHO Lec3.2.8.1 cells [25] as previously described [12].
N-glycosylation in these cells is arrested at the high man-
nose state enabling de-glycosylation by treatment with
endoglycosidase H/F1. The SIRPγ was purified from the
cell culture media using nickel affinity chromatography
followed by size exclusion chromatography [26]. The
FabOX117 and SIRPγ proteins were mixed in a 1:1 molar
ratio and incubated overnight at 4°C. The FabOX117:
SIRPγ complex was treated with Endo F1 to remove
the N-linked glycans then purified by size exclusion
chromatography.
Crystallization and structure solution
The FabOX117: SIRPγ (16.8 mg/ml) complex was crys-
tallized from 0.2 M magnesium acetate tetrahydrate,
20% w/v polyethylene glycol 3350 (Hampton PEG/Ion
Screen #25). Data were collected to 2.5 Å resolution at
Diamond Light Source beamline I03 from a single crys-
tal. Diffraction images each of 1.0° oscillation and 0.5 s
exposure were recorded on a ADSC Quantum 315 CCD
detector at a X-ray wavelength of 0.9763 Å. The crystal
Nettleship et al. BMC Structural Biology 2013, 13:13 Page 7 of 8
http://www.biomedcentral.com/1472-6807/13/13was soaked in a cryoprotectant solution containing 20%
(v/v) glycerol and 80% (v/v) crystallization reservoir so-
lution for about 10 s before being plunged into liquid ni-
trogen and maintained at 100 K under a stream of
nitrogen gas during data collection. Data were indexed,
integrated and scaled using HKL2000/SCALEPACK [27].
The crystal belongs to a space group of P21212 with unit
cell dimensions of a = 140.4 Å, b = 174.2 Å and c = 81.7 Å.
The solvent content is 54% by assuming 2 complexes in
one crystallographic asymmetric unit.
The structure of the FabOX117: SIRPγ complex was
solved by molecular replacement using program MOLREP
[28] and search models FabOX117 and SIRPα (PDB IDs:
3DIF and 2WNG). The orientations and positions of Fabs
were readily determined, while the domains of SIRPγ had
to be found separately by using individual domains of
SIRPα as search models. Structure refinement and model
rebuilding were carried out with REFMAC [29] and
COOT [30] respectively. Tight backbone and loose side-
chain NCS restraints were applied throughout the refine-
ment. Diffraction data and structure refinement statistics
are shown in Table 2. Structural comparisons used SHP
[31]. Structural images for figures were prepared with
PyMOL (http://www.pymol.org/). The coordinates and
structure factors have been deposited in the Protein Data
Bank under accession number 4I2X.
Analytical ultracentrifugation
Analytical ultracentrifuge experiments were performed on
a Beckman-Coulter Proteome Lab XL-I running version
5.8 of the data collection software. Data was obtained
using both absorbance and interference optics. Sedimenta-
tion velocity data was obtained at 40 000 rpm in 2 channel
meniscus-matching centrepiece cells (SpinAnalytical, NH,
USA), while sedimentation equilibrium data was obtained
at 15 000, 20 000, 28 000 and 36 000 rpm in 2 channel
centrepieces (Beckman, USA).
Data were scanned every 2 hours until equilibrium
had been reached, as determined by calculated RMSDs
between successive scans using SEDFIT v14.1 and
analysed using SEDPHAT. Loading concentrations were
1.0, 0.2, 0.1 mg/ml for Sirpγ and FabOX117 alone. These
corresponded to molar loading concentrations of 20, 4
and 2 μM for Sirpγ and 23, 4.2 and 2.1 μM for
FabOX117. For the mixtures, these were performed at a
total concentration of 1 mg/ml at molar ratios of 1:2, 1:1
and 2:1, respectively. These corresponded to molar load-
ing concentrations of 6.3/13.7 μM, 10/10 μM and 13.7/
6.3 μM. The buffer used throughout was 20 mM Tris–
HCl pH 7.5 200 mM NaCl. The solvent density and vis-
cosity were calculated to be 1.0070 and 1.002, respect-
ively using SEDNTERP [32]. The molecular weight and
partial specific volumes for FabOX117 was calculated
using SEDNTERP to be 48 380 Da and 0.7281 g/ml,respectively. The corresponding values for SIRPγ were
calculated on the basis of an additional 1.8 kDa of glyco-
sylation to the protein sequence and found to be 52
800 Da and 0.7321 g/ml, respectively. All data were
obtained at 20°C.
Data analysis of analytical ultracentrifuge data
Sedimentation velocity data were analysed using SEDFIT
v14.1, and sedimentation coefficients determined from the
weight averaged integration of the peaks using the integra-
tion functions contained in the software. Corrected sedi-
mentation coefficients (S20, w values) were noted for each
loading concentration and used to extrapolate back to in-
finite dilution to obtain values for S020:w for each species.
Sedimentation equilibrium data were excised using
SEDFIT v14.1 and then exported into SEDPHAT. Data
were then fitted to a heterogeneous association A + B ⇔
AB, where A = FabOX117 (light and heavy chain) and B =
SIRPγ monomer. Errors in the determined dissociation
constant were calculated within SEDPHAT using a Monte
Carlo routine, and errors were quoted at the 95% confi-
dence level.
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